

12 February 2026

Direct Healthcare Professional Communication (DHPC)

IXCHIQ ▼ powder and solvent for solution for injection Chikungunya vaccine (live)

MHRA Marketing Authorisation number PLGB 41385/0007

IXCHIQ Chikungunya vaccine: updates to restrictions of use following safety review

Dear Healthcare Professional,

Valneva, in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA), would like to inform you that the safety review for IXCHIQ is now complete. Following this review, the Commission on Human Medicines (CHM) has recommended restricting the use of this vaccine in individuals aged 60 years and older, and in individuals with hypertension, cardiovascular disease, diabetes mellitus, and/or chronic kidney disease further,

1. There are no changes to the product strength.
2. In addition, the vaccine should be given no later than 30 days prior to travel, by a healthcare professional with experience of conducting benefit risk assessments for live vaccines.
3. Caution is also advised in vaccinating individuals with two or more underlying chronic health conditions.

Background

In February 2025, IXCHIQ was approved in the UK, for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years and older. The product continues to be supplied as a lyophilized powder in single dose vials along with sterile water for injection as a solvent in pre-filled syringes.

As of 31 January 2026, 55 cases of serious adverse events following vaccination with IXCHIQ have been reported worldwide, thereof 8 from the UK. So far, 38 serious cases involved vaccinated individuals aged between 60 and 91 years, three of which resulted in death (thereof one assessed as probably related to vaccination by the local Health Agency). Many of the elderly patients affected also had underlying health conditions and the exact cause of these adverse events and their relationship with the vaccine have not yet been determined.

In the light of these findings and given that studies on IXCHIQ mainly involved people below 65 years of age, the Commission on Human Medicines (CHM) has recommended restricting the use of the IXCHIQ Chikungunya vaccine in people aged 60 years and over, and in individuals with hypertension, cardiovascular disease, diabetes mellitus, and/or chronic kidney disease.

In addition to the amendments to the indication age in the patient information leaflet (PIL), the PIL will also be updated to reflect this advice.

The UK Summary of Product Characteristics (SmPC) and PIL are available at <https://www.medicines.org.uk/emc/product/100652/smpc#gref>

Valneva will ensure that the product labelling is updated accordingly at the next possible opportunity. However, the product labelled with the indication 18 years and older is expected to remain in the UK market until the product expires.

For more information, the DSU is published : [IXCHIQ Chikungunya vaccine: updates to restrictions of use following safety review - GOV.UK](#)

Call for reporting

IXCHIQ ▼ is subject to additional monitoring. This will allow quick identification of new safety information. Please report ANY suspected adverse drug reactions (ADRs) to drugs and vaccines identified by the black triangle ▼ to the MHRA through the Yellow Card scheme.

Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

You can report via:

- the [Yellow Card website](#)
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, timing onset, treatment dates, and product brand name.

The non-identical nature of biological medicines and vaccines means it is very important that safety surveillance is carried out on a brand/product-specific basis. When reporting a suspected ADR to a biological medicine (such as blood products, antibodies and advanced therapies [such as gene and tissue therapy]) or vaccine, please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.

Additionally, when providing patients with details of the vaccine or biological medicine administered, it is good practice to give them details of the brand and batch number. This will allow patients and carers to more accurately report suspected ADRs to the Yellow Card scheme.

Company contact

If there are any questions, please contact through the details mentioned in the packaging material. You may also contact our medical information at medinfo@valneva.com or +43 1 20620 1444 if you have any questions about the information contained in this letter or the safe and effective use of IXCHIQ.

Healthcare professionals are asked to report any suspected adverse drug reactions in accordance with the national spontaneous reporting system and include batch/lot number if available.

Legal category: POM. **Packaging Quantities:** 1 vial of powder, 1 pre-filled syringe of solvent without needles. Basic cost: £113.00 per dose. **Marketing authorisation holder:** Valneva Austria GmbH. Campus Vienna Biocenter 3, A-1030 Vienna, Austria. **Marketing authorisation numbers:** PLGB 43185/0007

For full prescribing information and details of other side effects please refer to the Summary of Product Characteristics which can be found at

<https://products.mhra.gov.uk> or <https://www.medicines.org.uk/emc>

Full prescribing information is available on request from: Medical Information, VALNEVA AUSTRIA GMBH, Campus Vienna Biocenter 3, 1030 Vienna, Vienna, Austria, FB-Nr: FN 389960 x / HG Wien. Telephone: +44 1506 446608.

Email: infoixchiq@valneva.com

Adverse events should be reported.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Valneva via email: safety@valneva.com

Sincerely,

Ravi Birdee, Head of Medical Affairs